banner
 
bar

program

bar
 
 

ACS-WRAP:
Focus on Oral Antiplatelet Therapy
for Medical Management of ACS

MedicineWRAP CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium:

Internet-based program

Method of Physician Participation Utilized in Learning Process:

There are no fees for participating and receiving CME credit for this activity. During the period December 12, 2011 through December 12, 2013 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) register and complete the evaluation form; and 4) print out your CME certificate.

Estimated Time to Complete Educational Activity:

2.0 hours

Course Overview:

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in antiplatelet therapy for the management of acute coronary syndrome.

Release Date:

December 12, 2011

Expiration Date:

December 12, 2013

Intended Audience:

This program is intended for all cardiovascular-focused clinicians, investigators, program directors, and healthcare providers caring for patients with cardiovascular disease, ACS, and related conditions

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

logoThis activity is supported by an educational grant
from Bristol-Myers Squibb

Physician Continuing Education

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The University of Massachusetts Medical School designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity, and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials

Program Faculty and Disclosures:

Charles V. Pollack, Jr., M.A., M.D., FACEP
Professor and Chairman, Emergency Medicine
Pennsylvania Hospital
University of Pennsylvania Health System
Philadelphia

Faculty Disclosures
Dr. Charles Pollack discloses that he has been a consultant to Bristol-Myers Squibb, The Medicines Company, sanofi-aventis, Genentech and Schering-Plough. He has received direct research support from GlaxoSmithKline, and has been a speaker for Schering-Plough, Bristol-Myers Squibb, and sanofi-aventis.

Advisory Board/Consultant: Amgen, Merck, Roche, Sanofi-aventis
Stockholder: Omthera Pharmaceuticals

Program Managers and Web Editor Disclosure:

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives:

Physicians, pharmacists, and other healthcare providers will:

  • Be better educated about and more clinically proficient at implementing
    current ACC/AHA/ACEP/SCAI guidelines for management of UA/NSTEMI as
    these recommendations relate to use of antiplatelet and other antithrombotic
    agents in patients undergoing both acute and long-term medical
    management of UA/NSTE-ACS.
  • Become more aware of the role that each clinical specialty group and
    stakeholder—emergency physician, hospitalist, primary care/internal
    medicine, cardiologist—has for ensuring guideline-adherent implementation
    of antiplatelet therapy at each phase of the medical management cycle for
    ACS, including ED, hospital, CCU, pre- and post-angiography, hospital
    discharge, and post-hospital, enduring medical management of ACS.
  • Become more aware of the importance that multiple specialty groups
    involved in the ACS management cycle adhere to published, evidence-based
    guidelines as the core strategy for medical management of patients with
    ACS.
  • Be better educated about and more clinically proficient at optimizing
    medical treatment of NSTE-ACS, based on proper risk stratification strategies
    which will help identify patients who are best treated with a conservative
    (medical) approach for UA/NSTEMI, in both the acute and long-term settings.
  • Become more clinically skilled at identifying ACS patients who are
    amenable to a medical strategy for their treatment, and be better able to
    apply the results of landmark studies outlining how to implement a
    selectively invasive strategy for ACS, and what the impact is of medical-based
    strategies for ACS is one patient outcomes.
  • Be better educated and better able to implement dosing and evidence-based
    guidelines for long-term antiplatelet management of ACS (UA and
    NSTEMI) patients who, based on risk stratification criteria or findings at
    angiography, are appropriate for a long-term medical strategy employing
    antiplatelet agents and other cardioprotective therapies.
  • Be better educated, based on scientific evidence and clinical trial data, on
    how best to assess the need or suitability of medically managed ACS patients
    for specific genetic testing prior to antiplatelet therapy; and how to
    implement current, evidence-based standards of clinical practice endorsed by
    published guidelines, FDA, and Clinical Alerts issued by the ACCF/AHA.
  • Be better educated and understand the implications and risks associated
    with suboptimal treatment of medical managed ACS, and the comparative
    outcomes of patients managed with appropriate doses and duration
    guideline-mandated oral antithrombotic/antiplatelet therapy versus those
    receiving suboptimal medical therapy for ACS.
  • Be better educated about the foundation role of oral antiplatelet agents
    when managing acutely ill patients presenting to the ED or CCU with NSTEACS
    or STEMI, and more aware of guidelines and recommendations for
    continuing oral therapy in the post-hospitalization period.
  • Be better able to implement optimal dosing, duration of therapy, and
    timing strategies for antiplatelet agents, i.e. putting into practice, at all
    phases of ACS care, those approaches that produce the best balance of
    thrombosis mitigating outcomes and bleeding safety, for oral antiplatelet
    agents in the setting of medical therapy for ACS
  • Become more clinically skilled at initial risk stratification of patients
    presenting with UA or NSTE-ACS, as a basis for determining optimal,
    guideline-compliant approaches to antiplatelet therapy for initial and long-term
    post-ACS cardioprotection.
  • Become more educated about the pathophysiology, mechanisms of action,
    resistance, pharmacokinetics, and pharmacodynamics of antiplatelet agents
    and how these factors should impact clinical therapeutics for medical
    managed patients with ACS, including PPI-antiplatelet therapy interactions.
  • Become more skilled at interpreting and analyzing landmark trials and
    CRUSADE registry data in order to facilitate optimal drug selection, with a
    focus on implementing the optimal approach to timing, selection, dosing,
    combination therapy, and appropriate use of antiplatelet agents in the setting
    of NSTE-ACS and UA.
  • Become more aware of the implications of the CRUSADE, DUKE, GRACE,
    and REACH registries and how they have helped identify and illuminate
    clinical practice gaps in medical management of patients with ACS.
  • Better educated and skilled at applying AHA/ACC guidelines for
    management of NSTE-ACS and the Year 2008 STEMI Update, with a focus on
    timing of administration and special considerations for long-term antiplatelet
    therapy depending on risk stratification, invasive vs. non-invasive strategies,
    and CABG.
  • Better educated about the pharmacology, dose, and side effects of
    antiplatelet agents employed for medical management of ACS.
  • Become more proficient at prescribing strategies for antiplatelet agents that
    reduce side effects and increase the likelihood of optimal clinical outcomes in
    patients with ACS, including indications for using PPIs in combination with
    antiplatelet agents.
  • Be better able to characterize and distinguish among safety profiles and
    bleeding risks and efficacy characteristics of oral antiplatelet agents used to
    medically manage ACS patients in the acute and long-term, post-ACS, post-hospitalization setting.

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer:

Copyright © 2011 by CMEducation Resources, LLC All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, or the program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © 2011 Resources, LLC All rights reserved.


 
6

 

Key Program Topics Include:


ACCORD
ACS
Acute Coronary Syndrome
Adipocytes
Adiponectin
ALECARDIO
Aleglitazar
Aleglitazar
AMI
atherogenesis
Atherogenicity
Atherosclerotic Heart Disease
Atherothrombosis
BARI 2D Trial
Cardiometabolic
CHD
Clopidogrel
coronary heart disease

DCCT
Diabetes
Dual PPAR Agonists
dyslipidemia
Euro-Heart Survey
fenofibrate
Fibrate
FIELD
FPG
gemfibrozil
GIK
GLP-1
Glycemic Control
HbA1c
HDL,
HDL-C
Helsinki Heart Study
Hyperglycemia
Hyperglycemic

Insulin
ISAR-DIABETES
LDL
LDL-C
Lipid
MACE
Macrovascular
Muraglitazar
PERISCOPE
Peroxisome Proliferator-activator Receptors
Pioglitazone
PPAR
AMI
PPARa
PPARg
PPARd
PPAR-g agonism
Prasugrel

PROactive
Retinopathy Progression
Rosiglitazone
STENO-2
SYNCHRONY
HbA1c
SYNTAX
T2D
Glucose
T2DM
Tesaglitazar
Thiazolidinediones
triglyceride
Triglyceride/HDL-C
TRITON–TIMI 38
Type 2 Diabetes
TZD
Vascular Wall Disease